Genetic testing company 23andMe is going public via a special purpose acquisition company (SPAC). We'll update this page as new information becomes available.
November 12, 2024: 23andMe has announced it will be laying of 40% of its workforce after its dramatic share price fall.
November 5, 2024: DNA-testing company 23andMe is struggling, with its stock price down over 70% in the past year, and it has only narrowly avoided being delisted from the stock market.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.00 |
|---|---|
| 52-week range | $3.38 - $20.40 |
| 50-day moving average | $5.73 |
| 200-day moving average | $8.68 |
| Wall St. target price | $40.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-26.20 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3 from 2024-11-15
| 1 week (2024-11-08) | -33.04% |
|---|---|
| 1 month (2024-10-17) | -38.90% |
| 3 months (2024-08-16) | 774.89% |
| 6 months (2024-05-17) | 411.25% |
| 1 year (2023-11-17) | 252.90% |
|---|---|
| 2 years (2022-11-17) | -95.24% |
| 3 years (2021-11-17) | 216.2 |
| 5 years (2019-11-14) | N/A |
| Revenue TTM | $199.2 million |
|---|---|
| Gross profit TTM | $132.9 million |
| Return on assets TTM | -25.77% |
| Return on equity TTM | -154.21% |
| Profit margin | 0% |
| Book value | $7.69 |
| Market Capitalization | $99.8 million |
TTM: trailing 12 months
We're not expecting 23andMe Holding to pay a dividend over the next 12 months.
You may also wish to consider:
23andMe Holding's shares were split on a 1:20 basis on 15 October 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 23andMe Holding shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for 23andMe Holding shares which in turn could have impacted 23andMe Holding's share price.
Over the last 12 months, 23andMe Holding's shares have ranged in value from as little as $3.38 up to $20.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 23andMe Holding's is 1.261. This would suggest that 23andMe Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put 23andMe Holding's beta into context you can compare it against those of similar companies.
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.